醋酸乌利司他(Ulipristal Acetate) - 药物靶点：PR_在研适应症：怀孕，避孕_专利_临床

概要

基本信息

药物类型

小分子化药

别名

BR-UPS、Esmya、Fibristal

+ [24]

靶点

PR

作用方式

调节剂

作用机制

PR调节剂(孕激素受体调节剂)

治疗领域

泌尿生殖系统疾病其他疾病

在研适应症

怀孕避孕

非在研适应症

异常子宫出血子宫腺肌病贫血+ [6]

原研机构

HRA Pharma Development SARL

在研机构

Laboratoire HRA Pharma SA

浙江仙琚制药股份有限公司Orion Laboratories Pty Ltd.

+ [1]

非在研机构

Gedeon Richter (UK) Ltd.

PregLem SAGedeon Richter Romania SA

+ [5]

最高研发阶段批准上市

首次获批日期

欧盟 (2009-05-15),

避孕

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构/序列

分子式C30H37NO4

InChIKeyOOLLAFOLCSJHRE-ZHAKMVSLSA-N

CAS号126784-99-4

关联

110

项与醋酸乌利司他相关的临床试验

CTIS2023-504259-29-00

/ Not yet recruiting临床1期

- BLCL-ULI-FDA-02

开始日期2023-12-11

申办/合作机构

Laboratorios Leon Farma SA

CTIS2023-504258-36-00

/ Not yet recruiting临床1期

- BLCL-ULI-FDA-01

开始日期2023-09-01

申办/合作机构

Laboratorios Leon Farma SA

NCT05674513

/ Recruiting临床4期IIT

Disparities in Emergency Contraceptive Metabolism Dictate Efficacy

The purpose of this study is to learn more about why some people are at greater risk for oral emergency contraceptive failure while others are not. The investigators want to learn if genetic differences impact the risk of emergency contraception failure.

开始日期2023-01-09

申办/合作机构

Oregon Health & Science University

100 项与醋酸乌利司他相关的临床结果

登录后查看更多信息

100 项与醋酸乌利司他相关的转化医学

登录后查看更多信息

100 项与醋酸乌利司他相关的专利（医药）

登录后查看更多信息

987

项与醋酸乌利司他相关的文献（医药）

2025-03-01·Theriogenology

Foals born alive from mares with ultrasonographically assessed placental abnormalities: Neonatal health and development up to weaning compared to foals from healthy mares

Article

作者: Debes, Leonie ; Blanco, Miguel ; Venner, Monica ; Sieme, Harald ; Koether, Karoline ; Sielhorst, Jutta ; Vervuert, Ingrid

Little is known about the health status of foals born alive from mares treated for placental disease. The aims of the present study were (1) to compare the neonatal health status and health development during the rearing period of foals born from mares treated for ultrasonographically assessed placental abnormalities (UPA) to age-matched healthy foals from the same warmblood stud and (2) analyze the influence of mare's placental health on colostrum quality. Foals (n = 127) born from mares with UPA (UPA group; P) in 2017-2019 were compared to 127 foals born from healthy mares (control group; C). Sixty-six UPA mares showed subclinical placental abnormalities (PSc1) and 61 mares showed clinical placental abnormalities (PSc2). The colostrum quality assessed by refractometry showed that healthy mares had 42 excellent (>30 %), 73 good (20-30 %) and 6 poor (<20 %) colostrum, whereas UPA mares showed 29 excellent, 66 good and 26 poor colostrum quality (P < 0.001). The administration of high-quality colostrum was more frequent in the UPA group (17.5 %) than in C (7.9 %; P = 0.024). The mean (±SD) gestation length of UPA mares was shorter (330 ± 11 days) and foal birth weight lower (54.2 ± 7.3 kg) compared to the healthy pregnancies (335 ± 11 days; P = 0.002 and 57.0 ± 6.6 kg; P < 0.001). The number of foals with a reduced immunoglobin G concentration 14 h postpartum was significantly higher in PSc2 (P = 0.007). Foals born from UPA mares received foreign plasma (P 25.4 % vs C 4.2 %; P = 0.028) more frequently. Premature placental separation, the occurrence of the retention of fetal membranes, placental weight, foal vitality and the white blood cell count did not differ between groups. Regarding the health status of the foal in the neonatal period (1-14 days postpartum), 10 foals (8.1 %) born from UPA pregnancies showed maladjustment syndrome, whereas none of the foals in the control group showed this condition (P < 0.001). Foals from UPA mares developed diarrhea more often (P 31.4 % vs C 19.9 %; P = 0.042), whereas omphalitis, pneumonia, sepsis, meconium obstipation and contracted tendons did not differ between the groups. Multimorbidity and treatment were more frequent in foals born from UPA pregnancies (P 12.8 % vs C 4.7 %; P = 0.004 and 59.6 % vs 40.4 %; P = 0.007). In conclusion, foals born alive from UPA mares face decreased immunity and an increased risk of disease during the first 14 days postpartum. The study underlines that colostrum supplementation from a healthy mare seems essential in UPA pregnancies.

2025-02-11·Expert Opinion on Pharmacotherapy

Selective progesterone receptor modulators for the treatment of dysmenorrhea: an update

Review

作者: Tureli, Dilruba ; Giani, Milo ; Speciale, Anna Rosa ; Vannuccini, Silvia ; Fambrini, Massimiliano ; Ozpinar, Kubra ; Petraglia, Felice

INTRODUCTIONDysmenorrhea is a painful symptom associated with uterine contractions and menstrual bleeding and is treated by administering analgesic drugs. Since progesterone receptors (PRs) have a major role in regulating uterine tissues (myometrium and endometrium) physiology, oral contraceptives are used off-label for treating primary or secondary dysmenorrhea. The development of selective progesterone receptor modulators (SPRMs), a class of synthetic steroids with agonistic, antagonistic, or mixed effects in targeting PRs in different tissues, stimulated their possible clinical use for treating secondary dysmenorrhea related to uterine diseases (endometriosis, adenomyosis, uterine fibroids).AREAS COVEREDThe present review examines the development of the clinical trials and observational studies done with the different SPRMs for the treatment of dysmenorrhea in patients with uterine diseases.EXPERT OPINIONMifepristone, telapristone acetate and vilaprisan have antagonistic activity on PRs, whereas ulipristal acetate and asoprisnil have both potent antagonist and partial agonist effects.Since no studies have been done on primary dysmenorrhea, the different SPRMs have been evaluated in the treatment of endometriosis, adenomyosis and uterine fibroid-related dysmenorrhea.

2025-02-06·Inflammatory Bowel Diseases

Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upadacitinib Is Associated With Improved Clinical Outcomes and Quality of Life in Patients With Crohn’s Disease

Article

作者: Xuan, Si ; Shukla, Nidhi ; Loftus, Edward V ; Joshi, Namita ; Panés, Julian ; Louis, Edouard ; Lacerda, Ana P ; Kligys, Kristina ; Lee, Wan-Ju ; Bossuyt, Peter

AbstractBackgroundWe evaluated the association of achieving endoscopic outcomes at week 12 of induction with improvements in clinical outcomes and quality of life (QoL) at week 52 of maintenance in patients with moderately to severely active Crohn’s disease (CD) treated with upadacitinib (UPA).MethodsThis post hoc analysis evaluated data from 2 phase 3 induction trials (NCT03345836 and NCT03345849) and 1 maintenance (NCT03345823) trial. Clinical responders to 12-week induction therapy with UPA who also received 52-week maintenance treatment with UPA were included. Endoscopic response, remission, healing, and ulcer-free endoscopy were assessed at week 12. Meaningful improvements in clinical and QoL outcomes were evaluated at week 52.ResultsA significantly greater proportion of patients who achieved an endoscopic response at the end of induction, compared with patients who did not, attained Crohn’s Disease Activity Index (CDAI) remission (52.0% vs 34.6%; P ≤ .01), corticosteroid-free CDAI remission (50.0% vs 30.9%), Inflammatory Bowel Disease Questionnaire remission (52.6% vs 30.3%), and meaningful improvements in Functional Assessment of Chronic Illness Therapy—Fatigue response (46.7% vs 25.9%), overall work impairment (47.1% vs 26.5%), and daily activity impairment (53.3% vs 34.1%) (all P < .05) at week 52. Similar findings were observed for patients who achieved endoscopic remission, endoscopic healing, and ulcer-free endoscopy at the end of induction vs those who did not.ConclusionsEarly improvement in endoscopic outcomes after UPA induction treatment was associated with long-term meaningful improvements in clinical outcomes and QoL in patients with CD.Clinical Registration numberU-EXCEED induction trial (NCT03345836), U-EXCEL induction trial (NCT03345849), and U-ENDURE maintenance trial (NCT03345823).

30

项与醋酸乌利司他相关的新闻（医药）

2025-02-14

·生物制品圈

mRNA序列设计|编码区序列（CDS）设计与优化全解析

导读：mRNA序列设计是mRNA疫苗/药物开发的第一难关，序列骨架直接影响mRNA的稳定性、翻译效率和免疫原性等，是mRNA成功开发的关键决策之一。mRNA由编码区域（CDS）和非编码区域（5' cap、5' UTR、3' UTR和3' poly A尾）构成。其中编码区决定了经mRNA递送的功能性蛋白的成药潜力。本期文章菌菌将聚焦于CDS编码序列，结合mRNA巨头公司Moderna、BioNTech/辉瑞、Arcturus等实际应用案例解析其设计与优化策略。 01 mRNA序列全解析 5’ Cap的作用是保护mRNA不被外切酶降解、维持其结构稳定性，并与3’端的poly A尾、poly A结合蛋白（PAPB）和翻译起始因子蛋白协同作用，起始蛋白质的翻译。出于真核生物体内表达的考虑，mRNA常用的帽结构为Cap1。IVT mRNA常用的加帽方式包括酶法加帽和共转录加帽。 5’ UTR和3’ UTR的功能为调控mRNA的翻译，影响mRNA的稳定性。在mRNA疫苗/药物的研发过程，UTR的设计原则为：直接选取人高表达基因的mRNA、使用病毒来源UTR、或基于算法全新设计UTR序列。如前所述，poly A尾与Cap结构、poly A尾结合蛋白（PAPB）协同起始mRNA的翻译程序。已被证明有效的polyA序列包括长度在100~120 nt的纯A序列、或分段式polyA序列（例如辉瑞/BioNTech的30A + 10(GCAUAUGACU) + 70A）。除以上非编码的元件外，编码区域（CDS）的可翻译率无疑是至关重要的。CDS的设计和优化策略为：首先确定目标蛋白的氨基酸序列（天然蛋白序列或具有增强功能的突变体），其次是针对目标物种进行密码子优化。下文中菌菌将结合典型案例分析mRNA CDS的设计与优化，主要包括两个步骤：首先是设计目标蛋白氨基酸序列，再基于密码子设计并优化mRNA CDS序列。图示 mRNA序列设计原则 02 编码蛋白的氨基酸序列设计与优化 mRNA CDS序列的设计基础是确定目标蛋白的氨基酸序列。氨基酸排列顺序是蛋白质一级结构和高级结构的基础，直接决定蛋白质的生物学功能。天然活性蛋白的氨基酸序列是CDS序列设计的可选方案之一。然而，随着蛋白质工程的成熟发展，筛选或定向改造具有增强功能的突变体能够进一步改善蛋白或多肽分子的成药特性。这一工程化设计思维也逐渐应用于mRNA CDS序列的设计，相关典型案例如下：案例1：报告基因eGFP 绿色荧光蛋白（GFP, green fluorescent protein）来源于水母Aequorea victoria，能够在原核和真核生物体内表达荧光蛋白。2008年，发现和发展GFP蛋白的三位科学家Osamu Shimomura、Martin Chalfie 和Roger Tsien（钱永健）被授予了诺贝尔化学奖。然而GFP发光信号较弱，科学家发现了一种GFP突变体，得到了增强型绿色荧光蛋白（eGFP, enhanced green fluorescent protein）。相比天然版本的GFP，eGFP的荧光强度提高了35倍。目前，eGFP mRNA已成为mRNA研究领域必不可缺的工具，用于细胞转染对照、mRNA序列优化、目标蛋白示踪以及递送系统开发。图示耀海RNASci平台eGFP mRNA的细胞转染评估报告基因mRNA的使用对于LNP递送系统的开发至关重要，例如：绿色荧光蛋白mRNA、红色荧光蛋白mCherry mRNA、荧光素酶mRNA（Luciferase mRNA）等。耀海生物RNASci平台提供多种报告基因mRNA（转染级和高纯度级），在体内外均具备高表达水平，高质量满足mRNA的细胞转染和动物试验需求。欢迎垂询：13380332910。案例2：Moderna mRNA-3705（hMMUT多态性）基因/蛋白的多态性也是目标蛋白氨基酸序列选择的考量之一。 mRNA-3704和mRNA-3705是Moderna开发的针对甲基丙二酸血症/酸尿症（MMA）的管线，MMA最常见的致病因素是甲基丙二酰辅酶A变位酶（MMUT）缺陷或缺失。 mRNA-3704和mRNA-3705均编码人MMUT，二者的区别在于，mRNA-3704的第671位氨基酸是缬氨酸（V671），而mRNA-3705的671位氨基酸替换为异亮氨酸（I671）。mRNA-3705的编码序列的来源为健康人群MMUT在671位点的多态性。图示 Moderna mRNA-3704/3705的序列示意图案例3：Arcturus ARCT-810（OTC突变体）参考蛋白/多肽药物的开发，设计一种蛋白突变体以改善其半衰期等性能，也是mRNA上游设计中的重要步骤。 ARCT-810是Arcturus的在研管线，靶点为鸟氨酸氨甲酰转移酶（OTC），针对鸟胺酸氨甲酰基转移酶缺乏症（OTCD）。ARCT-810通过专有脂质纳米颗粒（LNP）将mRNA递送到细胞中，mRNA被翻译成功能性的OTC，使患者自身肝细胞产生具有生物学功能的OCT酶。相比野生型OCT酶，ARCT-810存在3个氨基酸位点的改变，从而提高了OTC的半衰期，且增加了与线粒体的结合。图示 Arcturus ARCT-810序列示意图案例4：ReCode RCT2100（CFTR突变体）囊性纤维化（CF）是由囊性纤维化跨膜传导调节器（CFTR）基因突变引起的疾病，会导致患者进行性气道损伤和呼吸衰竭。ReCode正在开发一款基于mRNA蛋白替代疗法的管线——RCT2100。RCT2100编码CFTR mRNA，利用选择性器官靶向（SORT）LNP通过雾化器吸入给药，将mRNA特异性递送至与疾病有关的器官、组织和细胞。 RCT2100的mRNA编码区经过了优化。野生型CFTR蛋白存在一个特定的水解热点，而ReCode优化后的CFTR mRNA相比野生型的水解热点明显减少，有效维持mRNA的稳定性和翻译效率。图示 ReCode RCT2100序列示意图 03 mRNA CDS序列的设计与优化基于以上策略确定了目标蛋白的氨基酸序列，下一步是针对氨基酸序列设计优化mRNA序列，常用的策略为密码子优化。据报道，两种密码子优化策略（复合密码子家族优化和家族内密码子优化）已成功用于商业化mRNA疫苗CDS区的优化，包括Moderna新冠疫苗mRNA-1273和BioNTech/辉瑞疫苗BNT-162b2。当前主要以CAI（密码子适应指数）作为密码子优化的参数。经密码子优化后，mRNA-1273的CAI约为0.98，BNT-162b2的CAI约为0.95，二者均相比天然新冠病毒S蛋白编码基因（CAI＜0.7）大幅提高。 3.1 复合密码子家族优化对于精氨酸（Arg）编码基因来说，人体内使用CGN的频率高于AGR。然而，在病毒基因组内却恰恰相反。例如，新冠病毒的刺突蛋白包含42个Arg残基，其中30个由 AGR 密码子编码，仅12个由 CGN 密码子编码。在mRNA疫苗的CDS序列优化方面，辉瑞/BioNTech采用了典型的复合密码子优化策略，在BNT162b2的CDS区域减少了8个AGR密码子，对应增加了CGN密码子的频率。Moderna开发的mRNA-1273也使用了这一策略，将其中28个AGR密码子替换成了CGN。类似地，高表达的人核糖体蛋白中，81%的亮氨酸通过CUN密码子编码。因此，在mRNA疫苗BNT162b2和mRNA-1273中，多数的UUR被替换为CUN。 3.2 家族内密码子优化家族内密码子优化的原则是替换为高表达基因优选且被最丰富的tRNA解码的最佳同义密码子。在编码Arg的密码子中，CGG被认为是CGN家族中的最优解。基于这一原则，BNT162b2和mRNA-1273对Arg密码子进行了优化。同样地，在谷氨酸（Glu）密码子优化方面，mRNA-1273中的GAN家族密码子全部替换成了GAG。图示 2款商业化mRNA疫苗的密码子优化策略 04 结语众所周知，mRNA通过表达目标蛋白发挥预防或治疗效应，因此在mRNA CDS序列设计中，目标蛋白分子的设计是重中之重。编码蛋白的一级结构（氨基酸序列）直接影响功能性蛋白在体内的稳定性、半衰期和活性等成药关键特性。这一偏上游的分子设计在公共文章中反而鲜少提及，菌菌在本文通过典型案例进行了详细阐述。其次，密码子优化能够改善mRNA在目标宿主的翻译效率，对于mRNA-蛋白剂量水平也必不可少。密码子优化是基因合成、分子生物学领域的重要部分，可借助的工具包括多家生物技术公司推出的线上工具、以及百度推出的LinearDesign。参考文献 [1] Coughlan KA, Eybye M, Henderson N, DeAntonis CM, et al. Improved therapeutic efficacy in two mouse models of methylmalonic acidemia (MMA) using a second-generation mRNA therapy. Mol Genet Metab. 2024 Sep-Oct;143(1-2):108560. [2] Markey McNutt, MD, PhD, FACMG. It Translates: An Update on the ARCT-810 mRNA for OTC Deficiency. SIMD Annual Meeting 2024. [3] Daniella I，Dmitri B， Ella A M， et al. Functional Rescue of CFTR by Aerosolized Delivery of Optimized CFTR mRNA Using ReCode LNPs in Primary Human Bronchial Epithelial Cells Derived From Patients With Cystic Fibrosis. American Thoracic Society (ATS) 2022 International Conference.2022. [4] Xia X. Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines. Vaccines (Basel). 2021 Jul 3;9(7):734. doi: 10.3390/vaccines9070734. 识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观，不代表本站立。

信使RNA疫苗

2025-01-24

·drugs

Abortion Pill Alternative Found in Morning-After Pill

FRIDAY, Jan. 24, 2025 -- When one abortion pill faces lawsuits, another may be waiting in the wings, a new study suggests. The study, published Jan. 23 in the journal NEJM Evidence , has found a potential alternative to the abortion pill mifepristone , offering yet another option at a time when access to reproductive health care faces increasing legal and political challenges. Researchers tested ulipristal acetate, the active ingredient in the emergency contraceptive pill Ella , as a substitute for mifepristone in the medication abortion regimen. The study found that when ulipristal acetate was used at double the typical dose of Ella followed by misoprostol, the regimen was 97% effective in terminating pregnancies up to nine weeks. No serious complications were reported among the 133 women who participated. All but four completed the termination of their pregnancies without further intervention, researchers reported. The findings dovetail with ongoing lawsuits targeting mifepristone, the only drug specifically approved for abortion in the United States. Typically, it works by blocking progesterone, a hormone necessary for pregnancy, and is followed by misoprostol, which causes contractions to end the pregnancy. Lead author Dr. Beverly Winikoff , president of the reproductive health research organization Gynuity Health Projects, told The New York Times that the U.S. Supreme Court’s 2022 decision to overturn Roe v. Wade increased her interest in exploring alternatives to mifepristone. “I was thinking, there’s maybe something else we can do,” Winikoff said. “Another option. And this one is already on the market.” It's important to note, however, that reproductive health experts warn that the study could fuel political controversy, because Ella is also marketed as a prescription morning-after pill to prevent pregnancy following unprotected sex. Abortion foes have long argued that morning-after pills like Ella can act as abortifacients, substances that cause abortion. These claims have been strongly debunked. Evidence shows that Ella, when taken at its standard 30-milligram dose, works by delaying ovulation, preventing fertilization. This study, which used a 60-milligram dose of ulipristal acetate combined with misoprostol, does not debunk the science of emergency contraception . But it may blur public perceptions of the line between contraception and abortion. “It’s going to put wind in the sails of abortion opponents who have been saying things like contraceptives can be abortifacients,” Mary Ziegler , a law professor and abortion expert at the University of California, Davis, told The Times. “This study being released will be difficult, I think, for abortion rights supporters to manage.” Kristi Hamrick , a spokeswoman for Students for Life of America, said her organization would “absolutely” consider litigation over Ella. “The pro-life movement should be vindicated,” Hamrick told The Times . “We’ve been arguing for years that Ella acts as an abortifacient.” While the results are promising, experts say more research is needed before ulipristal acetate could replace mifepristone. “We can’t change clinical practice based on this study,” Kelly Cleland , executive director of the American Society for Emergency Contraception, told The Times. Dr. Daniel Grossman , a reproductive health researcher at the University of California, San Francisco, called the findings “promising.” But he warned that “if because of this new evidence that at higher doses, ulipristal acetate could cause an abortion, that were to lead to ulipristal acetate being taken off the market for emergency contraception, that would be really, really bad.” The study was conducted in Mexico City and was co-led by researchers there. “The more uses we have for these medications, the harder it will be for people to take them away,” Dr. Paul Blumenthal , an emeritus professor of obstetrics and gynecology at Stanford University who was in an advisory group for the study, concluded. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

上市批准临床研究

2025-01-15

·药时空

Arcturus启动H5N1禽流感自复制mRNA疫苗1期临床试验

2025年1月10日，Arcturus Therapeutics（“Arcturus”）宣布，已启动自复制mRNA（sa-mRNA）疫苗ARCT-2304（LUNAR-H5N1）的1期临床试验研究（NCT06602531），用于预防由H5N1病毒引起的大流行性流感疾病。该临床试验正在美国的多个地点进行，旨在招募大约200名健康成年人（120名18-59岁的参与者；80名60-80岁的参与者），第一批参与者于2024年12月接种，中期研究数据预计将于2025年下半年公布。该临床研究由生物医学高级研究与发展局（BARDA）全额资助。 ARCT-2304，也称为LUNAR-H5N1，是一种sa-mRNA候选疫苗，采用Arcturus专有的LUNAR®递送技术和STARR® mRNA平台技术配制而成。sa-mRNA候选疫苗旨在肌肉注射后在宿主细胞内制造许多mRNA拷贝，以增强血凝素（HA）和神经氨酸酶（NA）抗原的表达，从而实现比传统mRNA疫苗更低的剂量。该技术可能比基于鸡蛋和细胞的技术更快地提供疫苗。冻干疫苗制剂在冰箱中稳定，从而简化了冷链储存并降低了分销风险。该初步临床试验的主要目的是评估ARCT-2304疫苗的三种不同剂量水平和两种不同疫苗接种方案的安全性和免疫反应。通过血凝抑制（HAI）、病毒微量中和（MN）和神经氨酸酶联凝集素测定（ELLA）来测量免疫反应。 Arcturus Therapeutics总裁兼首席执行官Joseph Payne表示：“在H5N1流感中临床验证我们的低剂量STARR® mRNA技术是迈向大流行准备的关键一步，我们的团队正在与我们在美国和全球的合作伙伴BARDA和CSL加紧合作。” 识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

疫苗信使RNA临床1期临床结果

100 项与醋酸乌利司他相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09687	醋酸乌利司他	G03XB02 G03AD02	DB08867

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
怀孕	美国	Laboratoire HRA Pharma SA	2010-08-13
避孕	列支敦士登	Laboratoire HRA Pharma SA	2009-05-15
避孕	冰岛	Laboratoire HRA Pharma SA	2009-05-15
避孕	欧盟	Laboratoire HRA Pharma SA	2009-05-15
避孕	挪威	Laboratoire HRA Pharma SA	2009-05-15

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
平滑肌瘤	申请上市	欧盟	Gedeon Richter (UK) Ltd.	2012-02-22
平滑肌瘤	申请上市	冰岛	Gedeon Richter (UK) Ltd.	2012-02-22
平滑肌瘤	申请上市	挪威	Gedeon Richter (UK) Ltd.	2012-02-22
平滑肌瘤	临床前	冰岛	Gedeon Richter (UK) Ltd.	2012-02-22
平滑肌瘤	临床前	列支敦士登	Gedeon Richter (UK) Ltd.	2012-02-22
平滑肌瘤	临床前	欧盟	Gedeon Richter (UK) Ltd.	2012-02-22
平滑肌瘤	临床前	挪威	Gedeon Richter (UK) Ltd.	2012-02-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04291001 (CTgov)	早期临床1期	避孕	40	ENG implant (ENG Implant Alone)	網夢積鹽齋廠網觸鬱齋(獵醖憲憲鏇築網範襯齋) = 衊壓衊膚衊淵選窪壓醖夢鏇壓憲艱簾範鏇簾網 (壓壓願齋窪構積簾鹽夢, 構蓋壓衊齋簾衊願鏇鹹 ~ 遞蓋範艱膚繭顧願鑰衊) 更多	-	2024-07-12
				ENG implant+oral ulipristal acetate (ENG Implant Plus Oral UPA)	網夢積鹽齋廠網觸鬱齋(獵醖憲憲鏇築網範襯齋) = 製夢繭艱糧膚獵獵鹽襯夢鏇壓憲艱簾範鏇簾網 (壓壓願齋窪構積簾鹽夢, 鬱鹹築廠襯廠觸糧膚襯 ~ 襯鏇製餘獵鹹簾願鹽鹽) 更多
NCT02213081 (CTgov)	临床4期	子宫内膜异位症 \| 盆腔疼痛	1	Ulipristal	網鹹遞網觸窪範鹽壓願(廠夢鑰憲蓋鬱夢繭鑰顧) = 製醖膚餘鑰淵齋範夢鑰網淵廠構艱餘憲窪簾壓 (壓糧衊獵簾蓋選蓋餘醖, 範襯憲獵廠齋夢願夢鏇 ~ 鏇築蓋蓋鏇積餘襯壓顧) 更多	-	2024-05-16
NCT00551616 (CTgov)	临床3期	避孕	2,221	CDB-2914 (CDB-2914)	構觸淵艱製襯構觸衊網(糧鑰醖壓網願夢壓衊鹹) = 廠簾鏇選膚遞選鹽範壓襯鏇窪鹹襯鑰鹹膚糧鹹 (範廠蓋醖糧鹽齋築鏇鏇, 糧簾餘襯窪鹽鏇鑰網遞 ~ 繭襯鏇範壓夢製餘廠獵) 更多	-	2022-03-16
				Levonorgestrel (Levonorgestrel)	構觸淵艱製襯構觸衊網(糧鑰醖壓網願夢壓衊鹹) = 網艱壓齋夢願顧餘繭鹹襯鏇窪鹹襯鑰鹹膚糧鹹 (範廠蓋醖糧鹽齋築鏇鏇, 選襯淵醖範顧膚範製繭 ~ 構顧顧鬱襯積鏇壓鹽繭) 更多
ACR2021	临床3期	类风湿关节炎	905	UPA 15 mg + csDMARDs in bDMARD-IR patients	選網夢構鏇願網鏇觸餘(顧壓簾衊餘鹹簾遞範選) = Among bDMARD-IR patients, the median (95% CI) time to 50% improvement in pain was longer in SELECT-BEYOND versus SELECT-CHOICE (16 [12, 20] versus 8 [8, 12] weeks) 襯齋鑰齋憲窪願淵選夢 (顧繭積齋壓觸願壓膚構 ) 更多	积极	2021-11-07
				UPA 15 mg + csDMARDs in csDMARD-IR patients
EULAR2021	N/A	银屑病关节炎 \| 强直性脊柱炎	2,102	UPA 15 mg QD	廠鬱觸夢夢觸廠醖範選(衊壓顧膚觸餘衊餘範築) = 選窪壓壓鹽製衊廠願築獵繭夢製獵膚襯鬱廠獵 (築範鑰觸蓋壓襯餘選糧 )	-	2021-06-02
				UPA 30 mg QD	廠鬱觸夢夢觸廠醖範選(衊壓顧膚觸餘衊餘範築) = 繭膚醖鏇齋衊積蓋積淵獵繭夢製獵膚襯鬱廠獵 (築範鑰觸蓋壓襯餘選糧 )
NCT00411684 (CTgov)	临床3期	避孕	1,623	CDB-2914	(遞遞顧選衊鹹顧遞窪鏇) = 築網艱網鑰範廠築餘鏇夢獵糧憲鏇鹹襯構糧繭 (繭鬱遞襯艱願網鬱選窪, 餘獵鏇繭餘願艱鹹餘淵 ~ 齋廠憲積範蓋醖膚遞鹹) 更多	-	2021-05-03
NCT01629563 (PEARLIV \| PEARL IV, CTgov)	临床3期	平滑肌瘤	451	PGL4001 5 mg (Ulipristal Acetate (PGL4001) 5mg)	遞窪衊鹽構淵簾蓋衊鑰(選衊鏇壓窪鹽衊積糧顧) = 鹽壓鹽廠選獵鹽艱齋鏇鹽蓋夢壓艱遞鹽憲蓋獵 (廠鹹選鹽憲觸齋醖夢齋, 淵餘積構觸觸積鹹廠範 ~ 願鑰製鏇簾鑰窪網遞醖) 更多	-	2019-09-04
				PGL4001 10 mg (Ulipristal Acetate (PGL4001) 10mg)	遞窪衊鹽構淵簾蓋衊鑰(選衊鏇壓窪鹽衊積糧顧) = 鑰觸膚襯艱獵壓鬱糧構鹽蓋夢壓艱遞鹽憲蓋獵 (廠鹹選鹽憲觸齋醖夢齋, 窪廠襯鹹鬱繭衊衊鹽廠 ~ 夢鏇齋蓋鏇憲糧壓餘蓋) 更多
NCT02147197 (CTgov)	临床3期	异常子宫出血 \| 平滑肌瘤	157	Placebo (Placebo)	襯壓繭餘鏇夢鏇製齋觸(選獵觸壓鬱選廠願淵築) = 願遞積鬱襯艱繭獵憲襯積鑰網構壓膚鹽積築夢 (鹽蓋繭憲膚憲窪艱遞襯, 齋網鬱鏇齋廠製鑰衊膚 ~ 網壓夢遞鏇窪廠觸艱鬱) 更多	-	2019-04-05
				Placebo+Ulipristal acetate (UPA) (UPA 5 mg)	襯壓繭餘鏇夢鏇製齋觸(選獵觸壓鬱選廠願淵築) = 壓繭獵夢艱襯積衊鬱選積鑰網構壓膚鹽積築夢 (鹽蓋繭憲膚憲窪艱遞襯, 簾壓選選遞齋構範遞鬱 ~ 觸淵糧鹹夢窪構繭築窪) 更多
NCT00290251 (Pubmed \| Fertil Steril)	临床2期	子宫肌瘤	72	Ulipristal acetate	鏇鏇繭築築夢窪夢網齋(餘窪壓襯繭鹽淵壓範範) = 襯餘憲鹹醖膚壓廠鹽襯鹽艱鬱糧遞醖艱繭齋襯 (衊願願夢築鹽蓋願鑰製 ) 更多	-	2019-04-01
				Placebo	餘築鬱壓築觸鹹淵窪壓(鑰窪醖鏇衊鏇襯蓋壓衊) = 窪願醖衊鬱夢淵願顧簾遞簾蓋選齋艱網憲窪壓 (構顧廠膚構鏇網餘醖積 ) 更多
NCT02147158 (Pubmed \| Obstet Gynecol)	临床3期	子宫肌瘤	432	5 mg ulipristal acetate	(觸夢蓋繭壓獵夢構夢壓) = 餘願艱選鏇夢蓋網鑰膚衊鹹醖獵鏇襯鹽艱廠範 (夢艱網選獵觸鬱夢繭艱, 33.3 ~ 51.1) 更多	积极	2018-11-01
				10 mg ulipristal acetate	(觸夢蓋繭壓獵夢構夢壓) = 糧窪鑰夢構鑰製鹽選艱衊鹹醖獵鏇襯鹽艱廠範 (夢艱網選獵觸鬱夢繭艱, 45.5 ~ 63.8) 更多